manual v2.0 changes and daers lawrence allan (hjf – daids) dr. oluwadamilola ogunyankin (rsc...
TRANSCRIPT
Manual v2.0 Changes and DAERSManual v2.0 Changes and DAERS
Lawrence Allan (HJF – DAIDS) Dr. Oluwadamilola Ogunyankin (RSC Safety Office)
Lawrence Allan (HJF – DAIDS) Dr. Oluwadamilola Ogunyankin (RSC Safety Office)
November 15, 2010HVTN Network Meeting. Seattle, WA
November 15, 2010HVTN Network Meeting. Seattle, WA
ObjectivesObjectives
Expedited Reporting Policy Distinguish changes in Manual v2.0• Define key terms
• New algorithm for reportability
• Causality assessment
Distinguish DAERS changes for Manual v2.0
2
Manual for Expedited Reporting Version 2.0Manual for Expedited Reporting Version 2.0
Manual v2.0 (dated Jan 2010) has been issued and posted on Regulatory Support Center (RSC) website
Primary goal of this revision is to align expedited reporting to International Conference on Harmonization – Serious Adverse Event (ICH-SAE) definition
• Fulfill the DAIDS’ regulatory requirements to Federal Drug Administration (FDA)
• Fulfill the DAIDS’ obligations to industry collaborators
3
Highlights: Major ChangesHighlights: Major Changes
Categories of expedited reporting
Clarification of Definitions
Terms used in the assessment of Relationship to Study Agent
Submission of updates
• Event resolution
• Increase in event severity of ongoing AEs
Timeframe for expedited AE reporting
• Reporting days
• Site investigator assessment and signature timeframe
4
Expedited Reporting of Adverse Events to DAIDSExpedited Reporting of Adverse Events to DAIDS
Two Reporting Categories:
The protocol (and any applicable Letter of Amendment) will specify which reporting category will be used
7
SAE Definition (ICH E2A)SAE Definition (ICH E2A)
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose:•Results in death
•Is life-threatening
•Requires inpatient hospitalization or prolongation of existing hospitalization
•Results in persistent or significant disability/incapacity
•Is a congenital anomaly/birth defect
•Is an important medical event that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above
9
Clarification on SAE Definition: Life-ThreateningClarification on SAE Definition: Life-Threatening
Life-threatening refers to an event in which the patient was at risk of death at the time of the eventIt does not refer to an event, which hypothetically, might have caused death if it were more severe (e.g. malignancy)
Grade 4 events are referred to as potentially life-threatening events as defined in the DAIDS AE Grading Table; a Grade 4 event does not automatically meet SAE criteria
• Asymptomatic male subject presents with AST & ALT > 400 IU/L
• Asymptomatic female subject presents with a Hgb of 6.5 g/dL
– Both events are Grade 4 events (per the AE grading table), but neither subject is “…at risk of death at the time of the event.”
10
Clarification on SAE Definition: HospitalizationClarification on SAE Definition: Hospitalization
The following types of hospitalization DO NOT require expedited reporting to DAIDS:Any admission unrelated to an AE (e.g. for labor/delivery, cosmetic surgery, administrative or social admission for temporary placement due to lack of a place to sleep)
Protocol-specified admission (e.g. for a procedure required by protocol)
Admission for diagnosis or therapy of a condition that existed before receipt of study agent(s) and has not increased in severity or frequency as judged by the clinical investigator
NOTE: Hospitalization is not an AE, but is an outcome
11
Clarification on SAE Definition: Congenital Anomaly/Birth Defect Clarification on SAE Definition: Congenital Anomaly/Birth Defect
Do not report clinically insignificant physical findings at birth, including those regarded as normal variants.
Report clinically significant anomalies and include all other findings (even if not individually significant).
Example: An isolated finding of polydactyly or Mongolian spot in an infant with no other findings would not be reported but polydactyly or Mongolian spot occurring with a major cardiac defect would be included in the SAE report of the major cardiac defect.
NOTE: DAIDS clarification
12
SUSAR Reporting CategorySUSAR Reporting Category
Used for some non-Investigational New Drug (non-IND) studies/trials using U.S. FDA-approved agents with approved dosages for approved indications in typical populationsAt the discretion of DAIDS
NOTE: Since the majority of HVTN protocols are for unapproved vaccine products, the SAE reporting category would apply most of the time.
14
SUSAR Reporting CategorySUSAR Reporting Category
For many HVTN studies, SUSAR reporting is used during the period of extended surveillance, after the main study reporting period has been completedFor a particular participant, “Main Study Reporting Period” typically means from study enrollment until completion of the main study or discontinuation from study participationIf the protocol specifies an extended period of surveillance via annual contacts, this period is known as the “Annual Health Contact Period” (after main study period, continuing for X years thereafter)During the annual health contact period, only SUSARs are reported
15
SAE vs. SUSAR examplesSAE vs. SUSAR examples
Hospitalization for lithium overdose, 9 months since last vaccination, 3 months after termination from the study. Assessed by site PI as not related. Identified during Annual Health Contact reporting period, SUSAR category of reporting
SAE: Yes (Hospitalization)
SUSAR: No
Category of reporting per protocol: SUSAR
Reportable: No
16
SAE vs. SUSAR examplesSAE vs. SUSAR examples
Marked injection site muscle atrophy with arm weakness affecting ADLs reported during an annual health contact visit,1 year after last study visit, 18 months since last vaccination. Considered related due to anatomical location and an isolated similar finding in animal toxicity studies. Identified during Annual Health Contact reporting period
SAE: Yes (Important medical event)
SUSAR: Yes
Category of reporting per protocol: SUSAR
Reportable: Yes
NOTE: All SUSARs are SAEs, NOT all SAEs are SUSARs
17
Reporting Category: SAE or SUSARReporting Category: SAE or SUSAR
Additional reporting requirements:A protocol may require other AEs to be reported on an expedited basis
• e.g. all liver toxicities (regardless of seriousness or severity)
The protocol will specify the additional AEs to be reported to DAIDS
18
Adverse Events Not Requiring Expedited Reporting to DAIDSAdverse Events Not Requiring Expedited Reporting to DAIDS
An SAE occurring before exposure to a study agent.
Immune reconstitution inflammatory syndrome (IRIS), even if the event otherwise meets the reporting criteria. IRIS is an intense immune reaction that may result from a response to HIV treatment and is an anticipated event for antiretroviral therapies.
20
Updated InformationUpdated Information
Sites must follow each AE until the AE is resolved or stable. For each event reported to DAIDS, sites are required to submit an updated report as soon as significant additional information becomes available. The following are examples that must be submitted:
• An updated report documenting the stable or resolved outcome of the AE, unless the initial report included a final outcome
• Any change in the assessment of the severity grade of the AE or the relationship between the AE and the study agent
• Additional significant information on a previously reported AE [e.g., cause of death, results of re-challenge]
• A change in the primary AE term from what was previously reported
21
Reporting TimeframeReporting Timeframe
Within 3 reporting days of site awareness that an event fulfills the protocol-defined criteria for expedited reporting to DAIDS
“Reporting Days” criteria:• Starts at 12:00 a.m. and ends at 11:59 p.m. (local time)
• A day is counted as a reporting day regardless of the time of day that awareness occurred.
• Monday through Friday count as reporting days.
• Saturday and Sunday not considered reporting days.
• Any holiday (U.S. or in-country/local) that occurs on a Monday through Friday counts as a reporting day.
23
Site Investigator SignatureSite Investigator Signature
A site physician investigator or sub-investigator listed on the 1572 or the IoR Agreement must:
Review and verify the completed report for accuracy and completeness
Sign the report
NOTE: This physician makes the site’s final assessment of the relationship to study agent(s)
24
DAERSDAERS
For sites where DAERS has been implemented, ALL expedited adverse events and supporting information MUST be submitted to DAIDS using DAERS
Use DAIDS EAE reporting form 2.0 if DAERS has not been implemented, or if the system is unavailable for technical reasons.
25
Grading Severity of EventsGrading Severity of Events
All events reported to DAIDS in an expedited timeframe must be graded for severity.Grading does not determine reportability to DAIDS.
Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0 - December 2004 (Clarification dated August 2009)
28
Relationship AssessmentRelationship Assessment
The terms used to assess the relationship of an event to study agent are:
30
Relationship AssessmentRelationship Assessment
When an SAE is assessed as “not related” to study agent(s), an alternative etiology, diagnosis, or explanation for the SAE should be provided.
If new information becomes available, the relationship assessment of any AE should be reviewed again and updated as required.
31
SCHARP’s AE Log CRFsSCHARP’s AE Log CRFs
SCHARP currently has 2 versions of the AE Log CRF.• One has 5 relationship categories (Definelty, Probably,
Possibly, Probably Not, or Not Related)
• The other has 2 relationship categories (Related or Not Related)
All ongoing studies will continue to use the five category AE Log CRF
All new studies (as well as HVTN 505 and LTFU), will use the two category AE Log CRF.
32
SCHARP’s AE Log CRFsSCHARP’s AE Log CRFs
For those studies using the five category AE Log CRF, but EAE Manual Version 2, please consider the following “mapping” guidance when documenting the SAE relationship in DAERS and on the AE Log CRF
“Mapping Strategy for Relationship Assessments Using Manual Version 2.0”
Manual V1.0 Manual V2.0
Definitely related Related
Probably related Related
Possibly related Related
Probably not related Not Related
Not related Not Related
This mapping strategy will be used during AE/EAE Reconciliation.
34
ExpectednessExpectedness
Expected AEs are events that have been previously observed with use of the study agent(s). It is not based on what might be anticipated from the pharmacological properties of the study agent.Listed in the investigator’s brochure (IB)
SAE reporting category: • Sponsor to determine expectedness
SUSAR reporting category: • Site physician to determine expectedness
35
ExpectednessExpectedness
For unapproved products: Expected AEs are determined on the basis of the IB. Events are unexpected if:Not listed in the IB
Occur at a specificity/severity that has not been previously observed
Expected based on the drug class, but not yet observed with the specific drug in this drug class
Occur at a greater frequency than anticipated
36
10 Nov 2010 – Subject enrolled into the study and randomized; receives 1st administration of study vaccine:• MRKAd5 HIV-1 gag/pol/nef OR Placebo for MRKAd5
13 Nov 2010 – Subject presents to the ER complaining of sudden onset of severe abdominal pain (no previous history of GI issues or alcohol abuse), and is admitted for further testing and evaluation. Labs on admission were significant for elevated lipase (350 IU/L; normal 7 - 60 IU/L).
15 Nov 2010 – Subject contacts the site and notifies them that she was admitted, and remains hospitalized.
38
Case StudyCase Study
Reporter and Site InformationReporter and Site Information
Site Awareness Date: “…when the clinical research site recognizes that an event fulfills the protocol-defined criteria for expedited reporting to DAIDS.”• Date serious adverse event (SAE) occurred
–13 Nov 2010
• Date site aware event occurred at a reportable level
–15 Nov 2010
39
Must submit within 3 ‘reporting days’ of site awareness
Timeline for SubmissionTimeline for Submission
Primary Adverse EventPrimary Adverse Event
Seriousness Criteria (select appropriate ICH-SAE criteria; more than one criteria can be selected)• Requires inpatient hospitalization or prolongation of
existing hospitalization
Primary Adverse Event • Abdominal Pain
Severity Grade• 4 – Potentially life-threatening
41
Primary Adverse Event (continued)Primary Adverse Event (continued)
Onset Date: The date the primary adverse event first occurred at the level requiring expedited reporting• 13 Nov 2010
Country of AE Origin: The country where the event occurred; may not necessarily be the same where the clinical site is located• USA
Status Code at Most Recent Observation: The status code of the subject at the most recent observation• Not Recovered/Not Resolved
Status Date: Date of the most recent observation of the subject• 15 Nov 2010
42
Case NarrativeCase Narrative
Provide information on reported primary AE Describe the clinical course, therapeutic measures,
outcome, relevant past medical history, concomitant medication(s), alternative etiologies, any contributing factors, and all other relevant information.
NOTE: Any significant information that doesn’t have a field in DAERS can be included in the case narrative (e.g., results of a re-challenge).
43
Study AgentStudy Agent
Not a free text field Choose study agent from drop down menu• MRKAd5 HIV-1 gag/pol/nef OR Placebo for MRKAd5
Exposure to and duration of use of study agent important information to assess the case• Ensure accuracy of information
• If unsure, please note that the date is estimated
44
Study Agent (continued)Study Agent (continued)
Relationship of Study Agent to Primary AE• Related
Dose• 1 milliliter
Date of First Dose• 10 Nov 2010
Date of Last Dose: The date the subject took the last dose prior to onset of the adverse event• 10 Nov 2010
45
Action Taken: Enter the study physician’s action taken with the study agent after awareness of the SAE• Temporarily Held
Action Date: Date has to be on or after the site awareness date (i.e., study physician can take action with study agent only after site is aware AE has occurred at a reportable level). If action taken is “Course Completed” or “Off Study Agent at AE Onset” action date can be left blank.• 15 Nov 2010
46
Study Agent (continued)Study Agent (continued)
Concomitant Medications:• None
Other Events: List other clinically significant signs and symptoms that more fully describe the nature, severity, and/or complications of the primary AE.
• None
Laboratory Tests (include normal range, if known):• Elevated lipase (350 IU/L; normal 7 – 60 IU/L)
Diagnostic Tests:• None
47
Concomitant medicationsLaboratory and Diagnostic tests Concomitant medicationsLaboratory and Diagnostic tests
Reporter: Completes and sends the report to submitter for final review
Submitter: Reviews and submits the report to DAIDS
Email notification of expedited report submission sent to CRS staff and other key stakeholders
NOTE: It’s the site’s responsibility to confirm that the report was in fact submitted.
48
Review and SubmissionReview and Submission
UpdateUpdate
17 Nov 2010 – Subject is discharged from the hospital; event is ongoing.
18 Nov 2010 – Subject seen at the study clinic and provides a copy of discharge summary with diagnosis of acute pancreatitis.
49
Update (continued)Update (continued)
Primary Adverse Event• Term: Acute pancreatitis
• Status Code: Recovering/Resolving
• Status Date: 18 Nov 2010
Case Narrative• Do not delete previous narrative when updating
Additional Information• Upload copy of the discharge summary
50
How to Report EAEsHow to Report EAEs
Reports must be submitted via DAERS:
• DAERS: via web
https://daidses.niaid.nih.gov/Phoenix
• For emergency use only:
– Fax: 1-301-897-1710
or
1-800-275-7619 (USA only)
– Email: [email protected]
• If e-mailing, scan or fax signature page
51
Where to Get HelpWhere to Get Help
RSC Safety Office:• E-mail: [email protected]• Telephone: + 1-301-897-1709
or 1-800-537-9979 (US Only)• Fax: +1-301-897-1710
or 1 -800-275-7619 (US Only) RSC Web Site: http://rsc.tech-res.com/ DAIDS-ES Support:
• E-mail: [email protected]• Telephone: +1-240-499-2239
or 1-866-337-1605 (US Only)• Fax: +1-301-948-2242
52